Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 957 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Stage II Clear all
Recruiting Phase 2 Interventional

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

NCT07218666
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma
Interventions
Zanzalintinib
Drug
Lead sponsor
Deepak Kilari
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00049257
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Withdrawn Phase 2 Interventional

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

NCT02065323
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard ADT, Dovitinib
Drug
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

NCT00313482
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Sargramostim, Docetaxel, Prednisone
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2012 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gefitinib plus etoposide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 3 Interventional

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04457245
View directory record Official record
Conditions
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

OGX-427 in Castration Resistant Prostate Cancer Patients

NCT01120470
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
OGX-427, Prednisone
Drug
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

NCT01215799
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Bafetinib
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer

NCT00082732
View directory record Official record
Conditions
Prostate Cancer
Interventions
behavioral dietary intervention, dietary intervention, therapeutic dietary intervention
Behavioral · Dietary Supplement · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 18, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

NCT06084338
View directory record Official record
Conditions
Prostate Cancer
Interventions
stereotactic ablative radiotherapy, Pluvicto, topical testosterone
Radiation · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
West Los Angeles, California • Hines, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2Phase 3 Interventional

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

NCT00004071
View directory record Official record
Conditions
Prostate Cancer
Interventions
leflunomide, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Boca Raton, Florida • Fort Myers, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

NCT02218606
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate 1000 mg po daily, Cabazitaxel 25 mg/m2 IV, prednisone 5 mg po BID
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 18, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT06330805
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 3 Interventional

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

NCT00005073
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1Phase 2 Interventional

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

NCT00283829
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, IL2
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 1 Interventional

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

NCT02767921
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer, Stage II Bladder Urothelial Carcinoma, Stage II Renal Cell Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy, Recombinant EphB4-HSA Fusion Protein, Therapeutic Conventional Surgery
Other · Procedure · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 18, 2026, 7:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT07336446
View directory record Official record
Conditions
Prostate Cancer
Interventions
AZD9750, AZD5305
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Duarte, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer

NCT02559115
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-RM2 (RM2), PET/CT Scan
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 2Phase 3 Interventional

A Long Term Safety Study With Atrasentan

NCT00127478
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older · Male only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
7
States / cities
Marina del Rey, California • Torrance, California • Aventura, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients

NCT01705652
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nexrutine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 18, 2026, 7:05 AM EDT